Aptar Digital Health, Enable Injections Team Up on enFuse Companion Digital Solution

Aptar Digital Health and Enable Injections Inc. have announced a strategic partnership, naming Aptar Digital Health as Enable’s preferred digital health partner for the enFuse system. The digital solution will aim to guide patients and caregivers throughout the injection process and help support engagement before, during, and after administration.

Through this partnership, Aptar Digital Health will deliver a companion digital solution for Enable Injections’ enFuse system to enhance the patient experience and support adherence-related programs. Key features may include treatment data recording, onboarding and training modules, injection guidance, patient-reported outcomes, and symptom tracking—helping to empower patients and caregivers with greater confidence and control over the treatment process.

“This collaboration seeks to enhance the treatment experience of patients beyond the moment of injection,” Enable Injections Chairman/CEO Michael D. Hooven said. “Together, we will combine innovative drug delivery with digital support tools. This can help patients remain engaged in their therapy and enable healthcare providers to better understand and support each patient’s journey.”

Built on a flexible and scalable architecture, the companion digital solution will be deployed alongside the enFuse system, enabling pharmaceutical partners to extend the value of their therapies beyond delivery. The digital solution may support use cases from clinical trials through commercialization, aligned with development and launch strategies.

Adherence data and patient-reported outcomes will be captured remotely, securely stored, and made available through analytics dashboards that generate actionable insights intended to support clinical development, launch readiness, and real-world use. The modular, program-specific design will allow partners to integrate digital components into their clinical or commercial programs based on their needs. By combining device-generated data with patient-reported insights, the digital solution will help drive more informed decisions grounded in real-world usage.

“We are excited to partner with Enable Injections to help bring the next generation of drug delivery solutions to life,” stated Damien McKeon, senior vice president of Strategic Partnerships at Aptar Digital Health. “Large-volume biologic therapies are increasingly used to treat complex chronic conditions. They often require long-term adherence to achieve optimal outcomes. Digital solutions supporting treatment tracking and patient engagement can help address common adherence challenges associated with self-administration.”

Aptar Digital Health creates end-to-end solutions to enhance patient experiences, leveraging a holistic ecosystem of digital interventions. Amplified by products and solutions, Aptar Digital Health’s offering combines mobile and web apps, Software-as-Medical-Device, connected drug delivery systems, advanced data analysis services, and patient onboarding and training solutions to actively empower patients and create a positive treatment journey. Headquartered in Crystal Lake, Ill., Aptar employs 14,000 workers across 20 countries.

Cincinnati-based Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of the enFuse on-body drug delivery system. A wearable technology, the enFuse system is designed to deliver large volumes of pharmaceutical and biologic therapeutics through subcutaneous administration to improve convenience, support improved outcomes, and advance healthcare system economics. Enable is currently working with various partners to conduct clinical trials and plan for the joint launch of their therapies in combination with the enFuse technology.